A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

• Status: NOT_YET_RECRUITING
• Trial end date: 2026-06-19

Summary

The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.

• Phase: PHASE1

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: apixaban; Enoxaparin; PRT064445; Rivaroxaban